The Development Of Drug Peptides Currently Presents Some Distinct Characteristics And Trends:

The development of drug peptides currently exhibits several distinct characteristics:

Driven by technological innovation: Whether it's the deep integration of AI (such as the AMP-Diffusion model and mRNA display technology) or novel delivery systems (such as biomimetic liposomes and brain-targeting strategies), technological breakthroughs are accelerating the discovery and optimization of high-quality drug peptides.

Addressing clinical challenges:
Research focuses on overcoming the inherent bottlenecks of drug peptides, such as poor stability, short half-life, weak membrane permeability (especially across the blood-brain barrier), and insufficient targeting.

Combination therapies and multifunctional integration:
Single molecules with multiple mechanisms of action (such as teriparatide), combined peptide therapies (such as the use of GLP-1RA with PYY), and integrated "delivery and treatment" systems (such as the PGFP system) are emerging as new ideas to enhance efficacy.

Expanding application boundaries:
Beyond traditional fields like metabolic diseases and cancer, drug peptides are showing great potential in neurodegenerative diseases (such as Alzheimer's disease) and anti-infection areas (particularly against resistant bacteria).

Challenges and future prospects
Although the prospects for drug peptide research and development are broad, there are still challenges to face: production costs, quality control in large-scale synthesis, evaluation of long-term toxicity and immunogenicity, and the development of more efficient delivery systems.

In the future, we can expect more functional peptides designed based on AI, the development of multi-specific peptides and peptide-drug conjugates (such as PDCs), and as delivery technology matures, more drug peptides will be able to break through barriers to treat brain diseases.